3.4.1. indications contraindications treatment hypogonadism. patients symptomatic hypogonadism (total testosterone < 12 nmol/l) without specific contraindications suitable candidates receive testosterone therapy (table 4). absolute contraindications untreated breast prostate cancer (pca). similarly, conditions cardiovascular events well uncontrolled poorly controlled congestive heart failure considered prescribing testosterone therapy . conversely, severe lower urinary tract symptoms (luts) [international prostate symptom score (ipss) score > 19] represent relative contraindication, insufficient data long-term effects testosterone therapy patients . positive family history venous thromboembolism requires analysis exclude condition undiagnosed thrombophilia-hypofibrinolysis . patients need carefully counselled prior testosterone therapy initiation. haematocrit (hct) > 54% require testosterone therapy withdrawal, reduction dose, change formulation venesection depending clinical situation avoid potential cardio-vascular complications. lower baseline htc (48-50%) carefully evaluated testosterone therapy initiation, avoid pathological increases treatment, especially high-risk men copd obstructive sleep apnoea syndrome (osas). accordingly, framingham heart study showed hct > 48% represented condition associated increased risk coronary artery disease (cad) mortality associated cardiovascular disorders . testosterone therapy suppresses gonadotropin endogenous testosterone secretion well spermatogenesis ; therefore, testosterone therapy contraindicated individuals desire fertility . secondary hypogonadism characterised low inappropriately normal gonadotropin levels; therefore, rationale substitute gonadotropin deficiency simultaneously fsh lh analogues, fertility desired . table 4: main contraindications testosterone therapy main contraindications testosterone therapyabsolute contraindicationslocally advanced metastatic prostate cancer (pca)male breast cancermen active desire childrenhaematocrit â‰¥ 54%uncontrolled poorly controlled congestive heart failurerelative contraindicationipss score > 19baseline haematocrit 48-50%familial history venous thromboembolism